Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 13;25(1):16.
doi: 10.1186/s40001-020-00414-5.

The role of passive immunization in the age of SARS-CoV-2: an update

Johannes C Fischer  1 , Kurt Zänker  2 , Martijn van Griensven  3 , Marion Schneider  4 , Detlef Kindgen-Milles  5 , Wolfram Trudo Knoefel  6 , Artur Lichtenberg  7 , Balint Tamaskovics  8 , Freddy Joel Djiepmo-Njanang  8 , Wilfried Budach  8 , Stefanie Corradini  9 , Ute Ganswindt  10 , Dieter Häussinger  11 , Torsten Feldt  11 , Hubert Schelzig  12 , Hans Bojar  13 , Matthias Peiper  14 , Edwin Bölke  15 , Jan Haussmann  8 , Christiane Matuschek  8
Affiliations
Review

The role of passive immunization in the age of SARS-CoV-2: an update

Johannes C Fischer et al. Eur J Med Res. .

Erratum in

  • Correction to: The role of passive immunization in the age of SARS-CoV-2: an update.
    Fischer JC, Zänker K, van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, Lichtenberg A, Tamaskovics B, Djiepmo-Njanang FJ, Budach W, Corradini S, Ganswindt U, Häussinger D, Feldt T, Schelzig H, Bojar H, Peiper M, Bölke E, Haussmann J, Matuschek C. Fischer JC, et al. Eur J Med Res. 2020 Oct 30;25(1):53. doi: 10.1186/s40001-020-00449-8. Eur J Med Res. 2020. PMID: 33126916 Free PMC article.

Abstract

The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.

Keywords: Bridge therapy; Convalescent plasma; Covid-19; High risk; Immunology; Intensive care unit; Respiratory failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
High activity natural killer cell during target attack. Footprint of previously attached natural killer cell can be identified by patchy membrane residuals on the target cell surface. Green objects have the size of budding virus particles. When will NK-cells join the cellular immune cascade to fight SARS-CoV-2?
Fig. 2
Fig. 2
The first donor at the University of Dusseldorf on 16.04.2020. Three plasmas can be generated with one blood donation
See this image and copyright information in PMC

References

    1. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;9:72. doi: 10.12688/f1000research.22211.2. - DOI - PMC - PubMed
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 With convalescent plasma. JAMA. 2020;323(16):1582–1589. doi: 10.1001/jama.2020.4783. - DOI - PMC - PubMed
    1. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 doi: 10.1172/JCI138745. - DOI - PMC - PubMed
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. doi: 10.1016/S1473-3099(20)30141-9. - DOI - PMC - PubMed
    1. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. doi: 10.1073/pnas.2004168117. - DOI - PMC - PubMed

LinkOut - more resources